Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.02
ICPT's Cash-to-Debt is ranked lower than
72% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ICPT: 2.02 )
Ranked among companies with meaningful Cash-to-Debt only.
ICPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.02  Med: No Debt Max: No Debt
Current: 2.02
Equity-to-Asset 0.43
ICPT's Equity-to-Asset is ranked lower than
77% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ICPT: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
ICPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.57 Max: 0.92
Current: 0.43
-0.13
0.92
Piotroski F-Score: 3
Altman Z-Score: 1.15
Beneish M-Score: 3.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1613.38
ICPT's Operating Margin % is ranked lower than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ICPT: -1613.38 )
Ranked among companies with meaningful Operating Margin % only.
ICPT' s Operating Margin % Range Over the Past 10 Years
Min: -8237.1  Med: -2022.81 Max: -766.2
Current: -1613.38
-8237.1
-766.2
Net Margin % -1654.63
ICPT's Net Margin % is ranked lower than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ICPT: -1654.63 )
Ranked among companies with meaningful Net Margin % only.
ICPT' s Net Margin % Range Over the Past 10 Years
Min: -16258.67  Med: -2981.9 Max: -705.71
Current: -1654.63
-16258.67
-705.71
ROE % -92.27
ICPT's ROE % is ranked lower than
78% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ICPT: -92.27 )
Ranked among companies with meaningful ROE % only.
ICPT' s ROE % Range Over the Past 10 Years
Min: -180.8  Med: -91.41 Max: -54.36
Current: -92.27
-180.8
-54.36
ROA % -62.08
ICPT's ROA % is ranked lower than
74% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ICPT: -62.08 )
Ranked among companies with meaningful ROA % only.
ICPT' s ROA % Range Over the Past 10 Years
Min: -140.05  Med: -62.75 Max: -49.77
Current: -62.08
-140.05
-49.77
ROC (Joel Greenblatt) % -3479.19
ICPT's ROC (Joel Greenblatt) % is ranked lower than
77% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ICPT: -3479.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ICPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8893.89  Med: -5930.8 Max: -2848.34
Current: -3479.19
-8893.89
-2848.34
3-Year Revenue Growth Rate 124.00
ICPT's 3-Year Revenue Growth Rate is ranked higher than
95% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ICPT: 124.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ICPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -39.65 Max: 124
Current: 124
0
124
3-Year EBITDA Growth Rate 94.30
ICPT's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ICPT: 94.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ICPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 48.55 Max: 94.3
Current: 94.3
-22.9
94.3
3-Year EPS without NRI Growth Rate 64.50
ICPT's 3-Year EPS without NRI Growth Rate is ranked higher than
93% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ICPT: 64.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ICPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -11.4  Med: 25.7 Max: 64.5
Current: 64.5
-11.4
64.5
» ICPT's 10-Y Financials

Financials (Next Earnings Date: 2017-05-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ICPT Guru Trades in Q1 2016

Steven Cohen 10,300 sh (New)
Columbia Wanger 187,043 sh (+0.09%)
George Soros Sold Out
» More
Q2 2016

ICPT Guru Trades in Q2 2016

George Soros 8,100 sh (New)
Columbia Wanger 233,573 sh (+24.88%)
Steven Cohen Sold Out
» More
Q3 2016

ICPT Guru Trades in Q3 2016

Columbia Wanger 192,510 sh (-17.58%)
George Soros 3,623 sh (-55.27%)
» More
Q4 2016

ICPT Guru Trades in Q4 2016

Steven Cohen 195,100 sh (New)
George Soros Sold Out
Columbia Wanger Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SAGE, NAS:CBPO, OTCPK:BTGGF, NAS:RARE, NAS:CLVS, NAS:AGIO, NYSE:XON, NAS:JUNO, NAS:PTLA, NAS:LGND, NAS:AVXS, NAS:PRTA, OTCPK:ABCZF, NAS:TBPH, NYSE:CBM, OTCPK:VNAPF, NAS:AAAP, NAS:NKTR, NAS:DBVT, OTCPK:MPSYY » details
Traded in other countries:I4P.Germany,
Headquarter Location:USA
Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with unmet medical need utilizing its bile acid chemistry.

Intercept is a biotech company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva for the treatment of primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of Japan, China, and Korea, where it has licensed out the product to Sumitomo Dainippon Pharma.

Top Ranked Articles about Intercept Pharmaceuticals Inc

Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017
Intercept to Present at Upcoming Conference

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
16th Annual Needham Healthcare Conference on April 4, 2017 at 11:20 a.m. Eastern Time Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks. About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT:
For more information about Intercept Pharmaceuticals, please contact:

Intercept Pharmaceuticals:
Mark Vignola
1-646-747-1000
[email protected]

Media inquiries: [email protected]

Investor inquiries: [email protected]

Read more...
Intercept to Present at Upcoming Conference

NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
Oppenheimer 27th Annual Healthcare Conference on March 21, 2017 at 3:55 p.m. Eastern Time Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks. About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT:
For more information about Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
1-646-747-1000
[email protected]

Media inquiries: [email protected]

Investor inquiries: [email protected]

Read more...
NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland

First new medication for primary biliary cholangitis in nearly 20 years Rapid NICE approval only two months after marketing authorization in the EU; one of the fastest approvals to date for an orphan medicine NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) (Intercept) today announced that the National Institute for Health and Care Excellence (NICE) has approved Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in England, Wales and Northern Ireland. Ocaliva has been conditionally approved in the European Union for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. The NHS is expected to make Ocaliva available to patients with PBC within 90 days of NICE’s final appraisal publication and Intercept will work with local reimbursement authorities to help ensure eligible patients obtain access.
Although it is a rare disease, PBC is a leading cause of liver transplantation in adult women in the UK. Ocaliva is a new treatment option for patients with PBC who do not fully respond to, or are intolerant to, current treatment and remain at risk of their disease progressing toward cirrhosis, liver transplantation or death. “I am excited to see that the substantial group of PBC patients who are not achieving treatment goals with UDCA alone or who cannot tolerate UDCA will soon be able to access the first new therapeutic option in nearly 20 years. This truly is good news for our PBC patients,” said David Jones, M.D., Ph.D., Professor of Liver Immunology at Newcastle University and Consultant Hepatologist at Newcastle upon Tyne Hospitals Trust, which hosts one of Europe's leading clinical services in the disease. “The development of new treatments for PBC is a powerful example of the medical innovation that can occur when government, industry, academia, community clinicians and, most importantly, patients come together to address an unmet need.” Ocaliva is a potent and selective agonist of the farnesoid X receptor (FXR), which is expressed at high levels in the liver and intestine and thought to be a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways. In December 2016, Ocaliva received conditional marketing authorization in Europe based on efficacy and safety data derived from three randomized double-blind, placebo-controlled clinical trials evaluating the effect of Ocaliva on alkaline phosphatase (ALP) and bilirubin in patients with PBC. The marketing authorization was also supported by two clinical databases that include more than 10,000 patients from the Global PBC Study Group and UK-PBC Group, both independently confirming that achieving lower ALP and/or bilirubin levels is significantly correlated with increased transplant-free survival. The most commonly reported adverse reactions were pruritus (63%) and fatigue (22%). Adverse reactions leading to discontinuation were 1% in the Ocaliva titration arm and 11% in the Ocaliva 10 mg arm. The most common adverse reaction leading to discontinuation was pruritus. The majority of pruritus occurred within the first month of treatment and tended to resolve over time with continued dosing. “This very rapid decision by NICE, one of the fastest approvals to date for an orphan medication, is an important affirmation of the scientific innovation, clinical value and cost-effectiveness of Ocaliva by one of the most respected health technology assessment bodies,” said Lisa Bright, Intercept’s President, International. “We welcome NICE’s decision to provide broad access to Ocaliva and we owe a tremendous debt to people living with PBC and the clinical groups who helped us to achieve this milestone for the PBC community.” “It is exciting news for PBC patients that this new treatment option will now be routinely available in England, Wales and Northern Ireland,” said Collette Thain MBE, CEO of The PBC Foundation. “When I was diagnosed with PBC, UDCA was the only approved treatment option and PBC wasn’t a major priority for many researchers. Thankfully, so much has changed for people living with PBC since then. After decades of advocacy from the PBC community, we have a new treatment option, a growing awareness of the disease among the general public, greater expertise amongst clinicians and an acceleration of PBC research in the UK and around the globe.” About Primary Biliary Cholangitis Primary biliary cholangitis (PBC) is a rare, autoimmune cholestatic liver disease that puts patients at risk for life-threatening complications. PBC is primarily a disease of women, afflicting approximately one in 1,000 women over the age of 40. If left untreated, survival of PBC patients is significantly worse than the general population. PBC in the UK The estimated prevalence of PBC in the UK is approximately 3.9 per 10,000 population, equating to approximately 19,175 people in England. Patients and medical leaders in the UK have played a critical role in accelerating PBC research, innovation and awareness globally. The patient community in the UK has guided Intercept’s efforts to improve PBC education and understand the unmet needs of patients and their families. The UK-PBC Study Group, a research consortium funded by the UK government through the Medical Research Council and National Institute for Health Research, played a critical role in the development of Ocaliva and was one of two clinical databases to independently confirm that achieving lower ALP and/or bilirubin levels is significantly correlated with increased transplant-free survival. About Ocaliva® (obeticholic acid) Ocaliva (obeticholic acid) is a potent and highly selective agonist of the farnesoid X receptor (FXR), a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways. In December 2016, Ocaliva received conditional marketing authorization in Europe for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA, conditional to the company providing further data post-approval to confirm benefit. In May 2016, the U.S. Food and Drug Administration granted accelerated approval to Ocaliva for the treatment of PBC. For full prescribing information in the U.S., visit Ocaliva.com. EU IMPORTANT SAFETY INFORMATION  Contraindications Hypersensitivity to the active substance or to any of the excipients and complete biliary obstruction. Warnings and Precautions Elevations in alanine amino transferase (ALT) and aspartate aminotransferase (AST) have been observed in patients taking obeticholic acid. Clinical signs and symptoms of hepatic decompensation have also been observed. These events have occurred as early as within the first month of treatment. Liver-related adverse events have primarily been observed at doses higher than the maximum recommended dose of 10 mg once daily. Patients should be monitored during treatment with Ocaliva for elevations in liver biochemical tests and for the development of liver-related adverse events. Dosage adjustments are needed for patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment. Severe pruritus was reported in 23% of patients treated with Ocaliva 10 mg arm, 19% of patients in the Ocaliva titration arm and 7% of patients in the placebo arms. The median time to onset of severe pruritus was 11, 158 and 75 days for patients in the Ocaliva 10 mg, Ocaliva titration and placebo arms, respectively. Management strategies include the addition of bile acid binding resins or antihistamines, dose reduction, reduced dosing frequency and/or temporary dose interruption. Adverse Reactions The most commonly reported adverse reactions were pruritus (63%) and fatigue (22%). Other common adverse reactions observed in clinical trials (> 5%) were abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality and eczema. Drug Interaction Bile acid binding resins such as cholestyramine, colestipol or colesevelam adsorb and reduce bile acid absorption and may reduce efficacy of obeticholic acid. When concomitant bile acid binding resins are administered, obeticholic acid should be taken at least 4-6 hours before or 4-6 hours after taking a bile acid binding resin, or at as great an interval as possible. For detailed safety information for Ocaliva (obeticholic acid) 5 mg and 10 mg tablets including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European Summary of Product Characteristics. About Intercept Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada. Intercept’s International headquarters are located in London. For more information about Intercept, please visit www.interceptpharma.com.   Safe Harbor Statements  This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical relevance and utility of ALP, bilirubin and the surrogate endpoint used in the Phase 3 POISE trial to predict clinical outcomes, the acceptance of Ocaliva® (obeticholic acid) as a treatment for PBC by healthcare providers, patients and payors, the commercial availability of OCA for the treatment of PBC and timelines related thereto, the anticipated prevalence of and other epidemiological estimates and market data related to PBC, the continued development of OCA and Intercept's other product candidates, and our strategic directives under the caption "About Intercept." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of important risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: Intercept's ability to successfully commercialize Ocaliva in PBC, and Intercept's ability to maintain its regulatory approval in jurisdictions in which Ocaliva is approved for use in PBC; the initiation, cost, timing, progress and results of Intercept's development activities, preclinical studies and clinical trials, including Intercept's development program in NASH; the timing of and Intercept's ability to obtain and maintain regulatory approval of OCA in PBC in countries outside the ones in which it is approved and in indications other than PBC and any other product candidates it may develop such as INT-767; conditions that may be imposed by regulatory authorities on Intercept's marketing approvals for its products and product candidates such as the need for clinical outcomes data (and not just results based on achievement of a surrogate endpoint), and any related restrictions, limitations, and/or warnings in the label of any approved products and product candidates; Intercept's plans to research, develop and commercialize its product candidates; Intercept's ability to obtain and maintain intellectual property protection for its products and product candidates; Intercept's ability to successfully commercialize OCA in indications other than PBC and its other product candidates; the size and growth of the markets for Intercept's products and product candidates and its ability to serve those markets; the rate and degree of market acceptance of any of Intercept's products, which may be affected by the reimbursement that it may receive for its products from payors; the success of competing drugs that are or become available; the election by Intercept's collaborators to pursue research, development and commercialization activities; Intercept's ability to attract collaborators with development, regulatory and commercialization expertise; regulatory developments in the United States and other countries; the performance of third-party suppliers and manufacturers; Intercept's need for and ability to obtain additional financing; Intercept's estimates regarding expenses, future revenues and capital requirements and the accuracy thereof; Intercept's use of cash, short-term investments and the proceeds from the offering; Intercept's ability to attract and retain key scientific or management personnel; and other factors discussed under the heading "Risk Factors" contained in our annual report on Form 10-K for the year ended December 31, 2016 filed on March 1, 2017 as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intercept undertakes no duty to update this information unless required by law.
Contact
For more information about Intercept Pharmaceuticals, please contact:

Mark Vignola
1-646-747-1000
[email protected]

Christopher Frates
1-646-757-2371
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.75
ICPT's PB Ratio is ranked lower than
83% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ICPT: 8.75 )
Ranked among companies with meaningful PB Ratio only.
ICPT' s PB Ratio Range Over the Past 10 Years
Min: 3.99  Med: 9.22 Max: 104.9
Current: 8.75
3.99
104.9
PS Ratio 109.92
ICPT's PS Ratio is ranked lower than
86% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ICPT: 109.92 )
Ranked among companies with meaningful PS Ratio only.
ICPT' s PS Ratio Range Over the Past 10 Years
Min: 42.02  Med: 1274.13 Max: 5193.93
Current: 109.92
42.02
5193.93
EV-to-EBIT -6.38
ICPT's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ICPT: -6.38 )
Ranked among companies with meaningful EV-to-EBIT only.
ICPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -200.1  Med: -15.3 Max: -3.6
Current: -6.38
-200.1
-3.6
EV-to-EBITDA -6.44
ICPT's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ICPT: -6.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -200.6  Med: -15.4 Max: -3.7
Current: -6.44
-200.6
-3.7
Current Ratio 9.02
ICPT's Current Ratio is ranked higher than
75% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ICPT: 9.02 )
Ranked among companies with meaningful Current Ratio only.
ICPT' s Current Ratio Range Over the Past 10 Years
Min: 4.69  Med: 11.29 Max: 16.62
Current: 9.02
4.69
16.62
Quick Ratio 9.02
ICPT's Quick Ratio is ranked higher than
76% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ICPT: 9.02 )
Ranked among companies with meaningful Quick Ratio only.
ICPT' s Quick Ratio Range Over the Past 10 Years
Min: 4.69  Med: 11.29 Max: 16.62
Current: 9.02
4.69
16.62
Days Sales Outstanding 133.51
ICPT's Days Sales Outstanding is ranked lower than
81% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ICPT: 133.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 80.28  Med: 131.16 Max: 535.77
Current: 133.51
80.28
535.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.60
ICPT's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ICPT: -8.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86  Med: -46.85 Max: -8.6
Current: -8.6
-86
-8.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.40
ICPT's Price-to-Net-Cash is ranked lower than
68% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ICPT: 10.40 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ICPT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.34  Med: 10.17 Max: 17.2
Current: 10.4
6.34
17.2
Price-to-Net-Current-Asset-Value 9.72
ICPT's Price-to-Net-Current-Asset-Value is ranked lower than
68% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ICPT: 9.72 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ICPT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.19  Med: 9.51 Max: 16.61
Current: 9.72
6.19
16.61
Price-to-Tangible-Book 8.76
ICPT's Price-to-Tangible-Book is ranked lower than
75% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ICPT: 8.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ICPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.05  Med: 8.59 Max: 16.07
Current: 8.76
6.05
16.07
Price-to-Median-PS-Value 0.09
ICPT's Price-to-Median-PS-Value is ranked higher than
97% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ICPT: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ICPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.58 Max: 1.47
Current: 0.09
0.04
1.47
Earnings Yield (Greenblatt) % -15.73
ICPT's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ICPT: -15.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ICPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3511.09  Med: 0 Max: 0
Current: -15.73
-3511.09
0

More Statistics

Revenue (TTM) (Mil) $24.95
EPS (TTM) $ -16.74
Beta1.98
Short Percentage of Float56.96%
52-Week Range $96.63 - 177.93
Shares Outstanding (Mil)24.83

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 111 255 504
EPS ($) -15.23 -11.56 -5.47
EPS without NRI ($) -15.23 -11.56 -5.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017 Apr 19 2017 
Intercept to Present at Upcoming Conference Mar 30 2017 
Intercept to Present at Upcoming Conference Mar 16 2017 
NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary Ch Mar 02 2017 
Intercept Pharmaceuticals Inc (ICPT) Moves Forward With OCA REGENERATE Trial; Buy Why Did Shares Sli May 20 2015 
Analysts are Positive on Intercept Pharmaceuticals Inc Following Quarterly Earnings and Pipeline Upd May 12 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST Mar 30 2015 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc, Ross Stores Inc, Sally Beauty Holdings In Mar 30 2015 
Intercept Pharmaceuticals Announces Two New Sub-Groups for FLINT Trial Mar 24 2015 

More From Other Websites
Should Gilead Sciences Be Worried About Allergan? Apr 23 2017
Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017 Apr 19 2017
Big Opportunity in Liver Treatment for Intercept Pharmaceuticals Apr 10 2017
ETFs with exposure to Intercept Pharmaceuticals, Inc. : April 7, 2017 Apr 07 2017
What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track Mar 31 2017
Intercept to Present at Upcoming Conference Mar 30 2017
These stocks are getting whacked after the GOP unveils its Obamacare replacement Mar 07 2017
Morningstar Runs the Numbers Mar 04 2017
Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales... Mar 03 2017
NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary... Mar 02 2017
Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017 Feb 27 2017
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat Feb 24 2017
Nasdaq Slips as Biotechnology Shares Decline Feb 24 2017
Edited Transcript of ICPT earnings conference call or presentation 23-Feb-17 1:30pm GMT Feb 23 2017
Intercept (ICPT) Reports a Wider Q4 Loss Feb 23 2017
Intercept reports 4Q loss Feb 23 2017
Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update Feb 23 2017
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More Feb 22 2017
Intercept (ICPT) to Post Q4 Earnings: What's in the Cards? Feb 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)